John Sarantopoulos

  • 1426 Citations
  • 20 h-Index
1991 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

Pharmacokinetics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Safety Medicine & Life Sciences
Tumors Chemical Compounds
Maximum Tolerated Dose Medicine & Life Sciences
Aurora Kinase A Medicine & Life Sciences
Liver Medicine & Life Sciences
docetaxel Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1991 2019

INSTITUTE FOR CANCER RESEARCH AND CARE

Hinck, A. P., Sarantopoulos, J., Curiel, T. J., Lafer, E. M., Weintraub, S. E., Karnad, A. B., Lechleiter, J. D., Thompson, I. M., Leach, R. J., Christy, B. A., Allred, C., Johnson, K., Padmanabhan, S., I-Tien, Y., Naylor, S., Gazitt, Y., Pollock, B. H., Mundy, G., Bonewald, L., Davis, S., Lee, E., Oishi, N., Hasty, E., Vijg, J. N. M. N., Herman, B. A., Johnson, K., Moyer, M., Windle, J., McGill, J., O'Connell, P., Clark, G., Kuhn, J., Wolf, R., Allred, D. C., Weiss, G., Boldt, D., Coltman, C. & Huang, H.

National Institutes of Health

9/1/917/31/19

Project: Research project

Neoplasms
Research
Health
Hispanic Americans
Financial Management

Research Output 1996 2019

  • 1426 Citations
  • 20 h-Index
  • 56 Article
  • 1 Comment/debate

Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction

Zhou, X., Lockhart, A. C., Fu, S., Nemunaitis, J., Sarantopoulos, J., Muehler, A., Rangachari, L., Bargfrede, M. & Venkatakrishnan, K., Jan 1 2019, In : Journal of Clinical Pharmacology.

Research output: Contribution to journalArticle

Aurora Kinase A
Lymphoma
Pharmacokinetics
Liver
Neoplasms
4 Citations (Scopus)

Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer

El-Khoueiry, A. B., Sarantopoulos, J., O’Bryant, C. L., Ciombor, K. K., Xu, H., O’Gorman, M., Chakrabarti, J., Usari, T. & El-Rayes, B. F., Feb 21 2018, (Accepted/In press) In : Cancer Chemotherapy and Pharmacology. p. 1-12 12 p.

Research output: Contribution to journalArticle

Pharmacokinetics
Safety
Liver
Neoplasms
varespladib methyl
1 Citation (Scopus)

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours

Nebot, N., Arkenau, H. T., Infante, J. R., Chandler, J. C., Weickhardt, A., Lickliter, J. D., Sarantopoulos, J., Gordon, M. S., Mak, G., St-Pierre, A., Tang, L., Mookerjee, B., Carson, S. W., Hayes, S. & Grossmann, K. F., Apr 1 2018, In : British Journal of Clinical Pharmacology. 84, 4, p. 764-775 12 p.

Research output: Contribution to journalArticle

Neoplasms
Pharmacokinetics
Area Under Curve
Placebos
Safety

Academic cancer center phase i program development

Frankel, A. E., Flaherty, K. T., Weiner, G. J., Chen, R., Azad, N. S., Pishvaian, M. J., Thompson, J. A., Taylor, M. H., Mahadevan, D., Lockhart, A. C., Vaishampayan, U. N., Berlin, J. D., Smith, D. C., Sarantopoulos, J., Riese, M., Saleh, M. N., Ahn, C. & Frenkel, E. P., Apr 1 2017, In : Oncologist. 22, 4, p. 369-374 6 p.

Research output: Contribution to journalComment/debate

Program Development
Neoplasms
Research
Research Personnel
Clinical Trials
9 Citations (Scopus)

A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma

Mahalingam, D., Fountzilas, C., Moseley, J., Noronha, N., Tran, H., Chakrabarty, R., Selvaggi, G., Coffey, M., Thompson, B. & Sarantopoulos, J., Apr 1 2017, In : Cancer Chemotherapy and Pharmacology. 79, 4, p. 697-703 7 p.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Melanoma
Patient treatment
Investigational Drugs